Related Experiment Videos
G-CSF-induced decrease of the anti-granulocyte autoantibody levels in a patient with autoimmune granulocytopenia
L T Vlasveld1, M de Haas, A A Ermens
1Department of Internal Medicine, Diaconessenhuis, Eindhoven, The Netherlands.
Annals of Hematology
|July 1, 1997
Summary
Granulocyte colony-stimulating factor (G-CSF) treatment rapidly increased granulocyte counts in a patient with autoimmune granulocytopenia. This led to reduced anti-granulocyte antibodies, possibly due to increased antibody adsorption by granulocytes.
Area of Science:
- Hematology
- Immunology
Background:
- Autoimmune granulocytopenia can occur alongside autoimmune thrombocytopenia.
- Understanding treatment responses and underlying mechanisms is crucial for managing these conditions.
Observation:
- An 81-year-old male patient presented with secondary autoimmune granulocytopenia and thrombocytopenia.
- Treatment involved granulocyte colony-stimulating factor (G-CSF) at 5 micrograms/kg/day subcutaneously.
Findings:
- G-CSF therapy rapidly increased circulating granulocyte counts, characterized by a left shift.
- Significant upregulation of Fc gamma receptors (CD64, CD32, CD16) and activation markers (CD11b, CD66b) was observed on granulocytes.
- A marked decrease in both cell-bound and circulating anti-granulocyte antibodies was noted post-treatment.
Implications:
- G-CSF treatment effectively mobilizes granulocytes and modulates their surface receptors.
- The findings suggest a potential mechanism where increased granulocyte numbers and receptor expression facilitate antibody adsorption, leading to reduced autoantibody levels.
- This case highlights a novel therapeutic response pathway in autoimmune granulocytopenia.